Q Global Advisors’s Starling Oncology STLN Stock Holding History

Q Global Advisors’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-40,000	Closed	-$398K	–	369
2021 Q3	$398K	Sell	40,000 -10,000	-20%	-$99.3K	0.33%	42
2021 Q2	$498K	Hold	50,000	–	–	0.35%	63
2021 Q1	$498K	Buy	+50,000	New	+$533K	0.13%	109

Other funds holding STLN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

PGM

Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return

AGM

Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Q Global Advisors's STLN Position: Q4 2021 in Review

Q Global Advisors sold out of Starling Oncology (STLN) in Q4 2021, closing a stake of 40,000 shares — an estimated $398K sold.

Q Global Advisors first reported a position in STLN in Q1 2021 and held it in 3 quarters. The position peaked at $498K in Q2 2021. 21 funds tracked by Wall St. Rank hold STLN as of Q4 2021.

Q Global Advisors reported no remaining Starling Oncology position as of Q4 2021 after selling out during the quarter.
Q Global Advisors sold 40,000 Starling Oncology shares in Q4 2021, an estimated $398K.
Q Global Advisors first reported a position in Starling Oncology in Q1 2021 and held it in 3 quarters.
Q Global Advisors's Starling Oncology position peaked at $498K in Q2 2021.
21 funds tracked by Wall St. Rank held Starling Oncology as of Q4 2021.

Based on Q Global Advisors's 13F filing for Q4 2021, filed 15 Feb 2022.